Want to see JP:4574 full AI Analyst Report?
4574 Stock Chart & Stats
¥305.00
-¥2.00(-0.62%)
At close: 4:00 PM EST
¥305.00
-¥2.00(-0.62%)
Day’s Range― - ―
52-Week Range¥246.00 - ¥335.00
Previous CloseN/A
Volume146.60K
Average Volume (3M)93.84K
Market Cap
¥13.32B
Enterprise Value¥10.36B
Total Cash (Recent Filing)¥4.14B
Total Debt (Recent Filing)¥1.32B
Price to Earnings (P/E)25.0
Beta0.68
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.23
Shares Outstanding50,636,900
10 Day Avg. Volume93,940
30 Day Avg. Volume93,840
Financial Highlights & Ratios
PEG Ratio6.05
Price to Book (P/B)1.76
Price to Sales (P/S)2.34
P/FCF Ratio28.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)12.9
Revenue Forecast (FY)¥6.75B
Bulls Say, Bears Say
Bulls Say
Reduced LeverageMaterial debt reduction to ~¥0.82B from prior years and sizable equity improves financial flexibility. Lower leverage reduces interest burden and default risk, enabling management to allocate cash toward R&D, manufacturing capacity, or opportunistic M&A without immediate refinancing pressure.
Positive Cash GenerationOperating and free cash flow turned positive and strengthened, supporting internal funding for operations and investment. Reliable free cash flow underpins sustainable product development and working capital, lowers dependency on external financing, and improves long-term resilience.
Revenue Stabilization & GrowthTop-line stabilization and resumed modest growth indicate recovering demand and better commercial execution. Steady revenue growth supports margin improvement via operating leverage, fosters predictable cash flow, and gives management runway to reinvest in pipelines or expand distribution.
Bears Say
Earnings VolatilityLarge swings from profit to multi-year losses signal structural inconsistency in earnings generation. Persistent volatility complicates capital allocation, forecasting, and stakeholder confidence, raising the risk that future downturns could quickly reverse the recent recovery without durable revenue or margin fixes.
Unproven Cash ConversionAlthough profits returned, weaker cash conversion in 2024 versus accounting earnings suggests working capital or accrual mismatches. If cash realization lags earnings, the company may face funding shortfalls for R&D or capex during stress periods, increasing reliance on external financing.
Shrinking Asset Base & Past Negative ROEA contracting asset base and historically negative returns on equity point to underinvestment or asset sales and weak capital efficiency. That constrains scale-up potential and raises questions about the company’s capacity to sustain growth or generate attractive long-term returns without rebuilding assets or improving utilization.
Taiko Pharmaceutical Co., Ltd. News
4574 FAQ
What was Taiko Pharmaceutical Co., Ltd.’s price range in the past 12 months?
Taiko Pharmaceutical Co., Ltd. lowest stock price was ¥246.00 and its highest was ¥335.00 in the past 12 months.
What is Taiko Pharmaceutical Co., Ltd.’s market cap?
Taiko Pharmaceutical Co., Ltd.’s market cap is ¥13.32B.
When is Taiko Pharmaceutical Co., Ltd.’s upcoming earnings report date?
Taiko Pharmaceutical Co., Ltd.’s upcoming earnings report date is Aug 13, 2026 which is in 28 days.
How were Taiko Pharmaceutical Co., Ltd.’s earnings last quarter?
Taiko Pharmaceutical Co., Ltd. released its earnings results on May 14, 2026. The company reported -¥1.89 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Taiko Pharmaceutical Co., Ltd. overvalued?
According to Wall Street analysts Taiko Pharmaceutical Co., Ltd.’s price is currently Overvalued.
Does Taiko Pharmaceutical Co., Ltd. pay dividends?
Taiko Pharmaceutical Co., Ltd. pays a Semiannually dividend of ¥3.5 which represents an annual dividend yield of N/A. See more information on Taiko Pharmaceutical Co., Ltd. dividends here
What is Taiko Pharmaceutical Co., Ltd.’s EPS estimate?
Taiko Pharmaceutical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Taiko Pharmaceutical Co., Ltd. have?
Taiko Pharmaceutical Co., Ltd. has 50,636,900 shares outstanding.
What happened to Taiko Pharmaceutical Co., Ltd.’s price movement after its last earnings report?
Taiko Pharmaceutical Co., Ltd. reported an EPS of -¥1.89 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.02%.
Which hedge fund is a major shareholder of Taiko Pharmaceutical Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4574
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Taiko Pharmaceutical Co., Ltd.
Taiko Pharmaceutical Co.,Ltd. operates primarily in the pharmaceutical sector and the field of infection prevention. The company manufactures and distributes various over-the-counter medications, including its well-known Seirogan and Seirogan Toi-A brands, which are formulated to alleviate symptoms such as loose stools, diarrhea, vomiting, and ailments stemming from food or water contamination. Additionally, it provides specific tablets for diarrhea relief and quasi-pharmaceuticals like the Trumpet Intestinal Regulator BF. In its infection control segment, Taiko Pharmaceutical produces and supplies a range of sanitation products under the Cleverin brand to wholesalers. This includes the Cleverin generator, a device engineered to emit low concentrations of chlorine dioxide gas. The company also leverages its proprietary Cleverin technology by supplying it through original equipment manufacturer (OEM) agreements and engaging in joint product development ventures with other businesses. Its products are exported to several countries, including the United States, Canada, Thailand, Vietnam, Malaysia, and Mongolia. Taiko Pharmaceutical Co.,Ltd. was founded in 1946 and is headquartered in Osaka, Japan.
Technical Analysis
Pharma Foods International Co., Ltd.
―
Wakamoto Pharmaceutical Co., Ltd.
―
Morishita Jintan Co., Ltd.
―
Fuso Pharmaceutical Industries,Ltd.
―
Nippon Chemiphar Co., Ltd.
―